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Influence of some dietary constituents on aluminum absorption and
retention in rats. Eight groups of female Sprague-Dawley rats were
treated with 281 mg Al(OH)3/kg/day by gastric intubation five times a
week for five weeks. Concurrently, animals in seven groups received
ascorbic acid (56.3 mg/kg/day), citric acid (62 mg/kg/day), gluconic acid
(62.7 mg/kg/day), lactic acid (28.8 mg/kg/day), malic acid (42.9 mg/kg/
day), oxalic acid (28.8 mg/kg/day), and tartaric acid (48 mg/kg/day) in
the drinking water. The eighth group did not receive any dietary
constituent in the water and was designated as the control group.
Animals were placed in plastic metabolic cages and urine was collected
during the treatment period. The liver, spleen, kidney, brain and bone
aluminum levels of each rat were measured, as well as the total amount
of aluminum excreted into urine. All the dietary constituents signifi-
cantly increased the aluminum concentrations in most of the tissues,
with ascorbic and citric acids showing the highest rate of aluminum
accumulation. In contrast, no significant differences between control
and treated rats were observed in the concentrations of aluminum
excreted into urine. In view of these results, we suggest that the effects
of the simultaneous ingestion of aluminum hydroxide and those dietary
constituents in uremic animals should be evaluated. Meanwhile, the
diet of uremic patients should be carefully monitored.
Aluminum is no longer considered to be a non-toxic element.
In the last decade, the knowledge of the clinical aluminum
toxicity has been substantially increased. Dialysate aluminum
content and aluminum-containing phosphate binding agents
have been identified as contributing to hyperaluminemia in both
hemodialyzed and nonhemodialyzed patients suffering from
chronic renal failure [1—5]. Elevated levels of aluminum in brain
and bone have been associated with several neurological dis-
eases and osteodystrophic lesions in hemodialyzed uremic
patients [1, 6, 7]. Moreover, aluminum is a proposed risk factor
in the etiology of various disorders such as Alzheimer's disease,
amyotrophic lateral sclerosis, parkinsonism dementia, and, in
some cases, osteomalacia in patients with normal renal function
[6, 8—10].
The health threat from dialysate fluids has been reduced by
the recommendation that the dialysate contains less than 10
xgf1iter of aluminum [111. However, many patients with predi-
alysis chronic renal failure are treated with aluminum-contain-
ing phosphate binders to prevent hyperphosphatemia. Alumi-
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num-containing antiacids are also widely used in non-
prescription medications for dyspepsia. Until the seventies, it
was thought that the gastrointestinal tract was an impervious
barrier to the passage of aluminum. In 1977, Kaehny, Hegg and
Alfrey [2] clearly demonstrated that the gastrointestinal tract is
a formidable barrier to the entry of aluminum but that it is not
impervious. Furthermore, renal function is necessary to elimi-
nate aluminum from the body [12]. Thus, both decreased
urinary excretion and increased gastrointestinal absorption of
aluminum are thought to be reasons why this treatment occa-
sionally leads to symptomatic disease due to aluminum toxicity
in patients with chronic renal failure [13—15].
In recent years, Slanina et al [16, 171 demonstrated that oral
intake of citric acid combined with a prolonged high ingestion of
aluminum hydroxide results in significant absorption and reten-
tion of the metal in the brain and bone tissues of rats. It has also
been observed that ingestion of aluminum compounds with
either fruit juices or citric acid causes a marked increase in
gastrointestinal absorption of aluminum in healthy subjects [18,
191, or in patients with chronic renal failure [15, 20]. Because of
citrate's ability to induce aluminum toxicity in uremic patients
and its potential to produce toxicity in normal subjects, it has
been suggested that the simultaneous usage of citrate and
aluminum compounds should be avoided [211. On the other
hand, it has recently been reported that in the gastrointestinal
tract the presence of various aluminum-complexing dietary
compounds in conjunction with gastric acid, solubilizes alumi-
num cations and may thus result in the equilibrium formation of
a soluble complex of aluminum, which by preventing reprecip-
itation, may result in aluminum absorption and elevated plasma
aluminum levels [22].
The present study was undertaken to determine if concurrent
ingestion of some dietary organic chelators and aluminum
hydroxide may increase the gastrointestinal absorption and
retention of aluminum in rats.
Methods
Female Sprague-Dawley rats (Panlab, Barcelona, Spain)
weighing 200 to 220 g were used. Animals were kept in
individual plastic metabolic cages which permitted separate
collection of urine and feces. Food (Panlab standard diet) and
drinking water were available ad libitum. The animal room was
equipped with automatic light cycles (12 hours light/dark), and
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Table 1. Aluminum concentrations (igig) in various tissues of rats given aluminum hydroxide and some dietary constituents














Al(OH)3 + citric 6.55 519abf 21.35 720ach 0.78 048bc •5 o.y°" 9.02 2.48w'
acid
Al(OH)3 + 1.51 0.36°" 7•74 294bdf 2.01 0.54a 0.62 033abf 10.20 514bdg
gluconic acid
Al(OH)3 + lactic 1.43 0.53° 17.36 6.86a 4.04 221ab 5.82 777 3.8&°
acid
A1(OH)3 + malic 3.18 277abf 17.18 0.80 0.49°" 0.83 6.55 418bcd
acid
Al(OH)3 + oxalic 3.74 l.58" 13.82 554g 2.12 l.87ad1 0.89 2.59 1.olce
acid
Al(OH)3 + tartaric 3.16 219abf 375 228de 0.43 0.35°" 2.24 4.87
acid
Values are mean SD. ND = Not detected; detection limit 0.05 g/g.
Values in the same column not showing a common superscript are significantly different (P < 0.05)
f,g.b Significantly difference from control group (P < 0.05, P < 0.01, P < 0.001, respectively)
relative humidity and temperature were maintained within a
range of 40 to 60% and 21 to 23°C, respectively.
Aluminum hydroxide, and ascorbic, citric, gluconic, lactic,
malic, oxalic, and tartaric acids were obtained from E. Merck
(Darmstadt, Germany). Rats were divided into eight groups (6
animals/group) and were treated with 281 mg Al(OH)3/kg/day
(==' 100 mg Al/kg/day) by gastric intubation, five times a week for
five weeks. The concentrations of the solutions were prepared
so that a 200 g animal would receive 0.50 ml. Concurrently,
animals in seven groups received ascorbic acid (56.3 mg/kg/
day), citric acid (62 mg/kg/day), gluconic acid (62.7 mg/kg/day),
lactic acid (28.8 mg/kg/day), malic acid (42.9 mg/kg/day), oxalic
acid (28.8 mg/kg/day), or tartaric acid (48 mg/kg/day) in the
drinking water. Solutions were prepared daily to adjust the dose
to achieve a constant intake by taking into account the differ-
ences in body weight and fluid intake. The eighth group served
as control, and did not receive any dietary factor in the water.
To reduce the possible aversive effects of the acids (taste) sugar
was added to the drinking water of all groups (including
controls). Weight gain, and fluid and food intake were recorded
daily or twice a week, whereas urine was collected daily. After
five weeks, the animals were killed and brain, bone (femur),
kidneys, liver, and spleen were removed. Urine and tissue
aluminum concentrations were determined by atomic absorp-
tion spectrophotometry (Perkin-Elmer Model 4000 and HGA-
400 graphite furnace with AS-40 autosampler). To reduce the
substantial number of analyses, urine samples of each rat were
pooled weekly and analyzed subsequently. Consequently, the
amount of aluminum measured in the total urine collected
during the five weeks of treatment was the result of five
analyses/rat.
For aluminum analysis, 1 ml of urine or about 500 mg of
tissue was placed in a 15 ml tube which had been rinsed five
times in ultrapure water. Digestion was accomplished by adding
ultrapure nitric acid (Suprapur 65%, E. Merck) and heated
under pressure at 190°C [231. Samples were then brought to a 10
ml volume with ultrapure water. To eliminate aluminum con-
tamination as much as possible from the environment, all
specimen manipulations were performed in a laminar flow hood
located in a limited-access room. To minimize matrix effects,
samples for standard curves were prepared by the method of
standard additions. Procedure blanks (reagents only) were read
with each group of samples. Absorbance readings for blanks
were substracted from sample readings prior to reference to the
standard curve [16, 17]. The coefficients of variation for the
different samples were between 4.2 and 7.3%. The percentage
recovery under the experimental conditions used was found to
be 98.2 8.3%.
Test groups were compared to the control group using a
Kruskal-Wallis one-way analysis of variance, with significant F
values analyzed further using Mann-Whitney U test. One-way
analysis of variance and Duncan's multiple-range test were
used to evaluate statistical significance among groups receiving
dietary constituents. A probability value of P < 0.05 was
accepted as significant. All results represent the mean SD.
Results
There were no significant differences between the dietary
constituents-treated groups and the control group in body
weight gain or food consumption during the period of treatment
(data not shown). Fluid intake was only significantly decreased
in the groups receiving lactic or malic acids at the third or fourth
week of treatment, respectively.
The concentrations of aluminum in liver, spleen, kidney,
brain and bone of control and dietary factors-treated rats are
shown in Table 1. In the control animals, the highest aluminum
levels were found in the spleen followed by the bone tissue,
whereas, aluminum was not detected in the brain. Treatment
with ascorbic or citric acids significantly increased the alumi-
num levels in liver (P < 0.05), spleen (P < 0.001), brain (P <
0.05), and bone (P < 0.001). Liver aluminum concentrations
were also raised by the intake of malic, oxalic, or tartaric acids
concurrent with the administration of Al(OH)3. In addition, all
the dietary constituents tested significantly increased the alu-
minum concentrations in brain, spleen and bone, with the
exceptions of tartaric acid in spleen, and malic and oxalic acids
in bone.
When statistical comparisons were carried out among groups
given aluminum hydroxide and dietary constituents, remark-
able differences could be observed in a number of tissues. Thus,
600 Domingo et a!: Dietary constituents and Al absorption
aluminum concentrations in spleen were significantly higher in
all test groups compared with the group given tartaric acid. The
concentrations of aluminum in the kidneys of rats receiving
ascorbic acid were significantly different from those given
citric, malic or tartaric acids, whereas significant differences
were also noted between citric, gluconic and lactic groups
compared with malic, oxalic and tartaric groups. In contrast, no
significant differences between control and dietary factors-
treated animals were noted in aluminum kidney levels. With
regard to bone, aluminum concentrations in the animals given
ascorbic acid were significantly higher than those detected in
the other groups, whereas bone aluminum levels were signifi-
cantly reduced in the group given oxalic acid compared with the
remaining ones (Table 1).
No significant changes in the amounts of aluminum measured
in the total urine collected during the five weeks of treatment
were seen between control and dietary factors-treated rats, or
among groups given aluminum hydroxide and the different
dietary constituents tested (data not shown). It has been re-
ported that in individuals with normal renal function, most if not
all absorbed aluminum is excreted in urine [241.
Discussion
It is well established that oral consumption of aluminum
compounds to neutralize stomach acid or to bind phosphate can
result in aluminum absorption and potential aluminum accumu-
lation and toxicity [251. In the last decade, it has been clearly
demonstrated that concurrent ingestion of aluminum com-
pounds and citrate causes a significant increase in the gastroin-
testinal absorption of aluminum in both healthy subjects and
patients with chronic renal failure [15—18, 20, 211. The increased
aluminum absorption has been attributed to the chelating prop-
erties of citric acid [26, 271. Oral citrate solubilizes Al3, and an
appreciable fraction occurs as a neutral complex that may pass
through membranes and provide a vehicle for aluminum absorp-
tion into the body [27]. On the other hand, parenteral adminis-
tration of citric acid has been shown to enhance the aluminum
urinary excretion after acute or subchronic aluminum intoxica-
tion [28]. This fact, which corroborates the great stability of the
citrate-aluminum complexes, may mistakenly suggest that the
same ligand plays opposite roles towards the same metal ion,
favoring the gastrointestinal absorption and enhancing the
aluminum excretion. Notwithstanding, the reason is that in
different biofluids where different pH and reactant concentra-
lions prevail, different complexes predominate, and the same
chemical partners can then induce different clinical effects [28,
291.
Recently, Partridge et al [22] have studied in perfusates of rat
gut the influence of some aluminum organic chelators that, like
citric acid, are frequently present in the diet as food additives.
These authors have reported that ascorbic, gluconic, lactic,
malic, oxalic and tartaric acids, as well as citric acid may
prevent the precipitation of aluminum hydroxide at the pH
conditions expected in the intestine. Because of the interest of
the question, in the present study we have investigated in vivo
the effects of these compounds on the gastrointestinal absorp-
tion and retention of aluminum. The administered quantities of
citric acid, 62 mg/kg/day, corresponded approximately with the
estimated daily dietary human intakes [30], The amounts in
moles of the other compounds are equivalent to the amount of
citric acid.
From the above reported results, it can be seen that ascorbic
acid—like citric acid—significantly increased the tissue accu-
mulation of aluminum, whereas both compounds did not raise
the urinary excretion of the metal. In fact, none of the various
chelators tested significantly altered the elimination of alumi-
num into urine, although gluconic, lactic, malic, oxalic and
tartaric acids also significantly increased the aluminum reten-
tion in most of the examined tissues. These results corroborate
the previous investigations by Partridge et al [22] on the
influence of some dietary constituents on intestinal absorption
of aluminum.
On the other hand, Fulton and Jeffery [311 recently reported
that citrate and ascorbate enhanced excretion of aluminum
when administered to rabbits in the drinking water containing
aluminum chloride (0, 100, or 500 mg AlJIiter) together with
citrate (0.11 M) or ascorbate (0.11 M) for 12 weeks. Although
they found that citrate significantly enhanced bone aluminum
levels, ascorbate did not increase aluminum accumulation in
any tissue studied, and even prevented accumulation in bone
[311. The differences with our results and those by Partridge et
al [221 may be due to the substantially different experimental
conditions between the respective investigations. We adminis-
tered both citric or ascorbic acids at significantly lower concen-
trations than Fulton and Jeffery [31]. Moreover, these authors
administered aluminum (as aluminum chloride) continuously in
the drinking water, whereas in our study aluminum was given
by gavage as aluminum hydroxide, which is remarkably less
soluble than aluminum chloride. However, in order to clear up
these differences, an additional study in which aluminum hy-
droxide and ascorbic or citric acids are administered simulta-
neously to rats at the doses given in the present investigation
should be performed.
Because of the wide use of the previous dietary constituents,
we also suggest that the effects of the concurrent ingestion of
aluminum hydroxide and these chelators by uremic animals are
clearly evaluated. It must be taken into account that the use of
significant quantities of these compounds as food additives is
usually considered safe. Meanwhile, because of the propensity
of uremic patients to retain aluminum even if not given oral
aluminum compounds, to prevent the potential aluminum accu-
mulation and toxicity, a careful surveillance of the diet of
chronic renal failure patients should be maintained. Also, with
regard to the specific problem of the therapeutic use of citrate,
we agree with Molitoris et al 121] in suggesting the alternative
use of sodium bicarbonate and calcium carbonate or calcium
acetate as substitutes for Shohi's solution and calcium citrate,
respectively.
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